Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer

Journal of the National Cancer Institute

Volumn 106, Issue 12, 2014, Pages

  Stellas, Dimitris ^a   Szabolcs, Matthias ^b   Koul, Sanjay ^b   Li, Zhe ^c   Polyzos, Alexander ^a   Anagnostopoulos, Constantinos ^a   Cournia, Zoe ^a   Tamvakopoulos, Constantin ^a   Klinakis, Apostolos ^a   Efstratiadis, Argiris ^a  

^a Academy of Athens Biomedical Research Foundation   (Greece)

^b NewYork Presbyterian Hospital   (United States)

^c REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1H PYRAZOLE 4 CARBOXYLIC ACID 5 [[[7 (CHLORODIFLUOROMETHYL) 5 (2 FURANYL)PYRAZOLO[1,5 A]PYRIMIDIN 2 YL]CARBONYL]AMINO] 1 PHENYL ETHYL ESTER; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG; 5-(4-ETHYLBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE; KRAS2 PROTEIN, MOUSE; MYC PROTEIN; MYC PROTEIN, MOUSE; PROTEIN P21; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER PREVENTION; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOUSE; NOD SCID MOUSE; NONHUMAN; ONCOGENE K RAS; ONCOGENE MYC; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, PANCREATIC DUCTAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE TARGETING; GENETICS; MALE; NONOBESE DIABETIC MOUSE; PANCREATIC NEOPLASMS; POSITRON EMISSION TOMOGRAPHY; SCID MOUSE; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCK-IN TECHNIQUES; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS P21(RAS); THIAZOLES; TOMOGRAPHY, X-RAY COMPUTED; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922394070     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju320     Document Type: Article

References (39)

1. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399-405.
2. Politi K, Kljuic A, Szabolcs M, Fisher P, Ludwig T, Efstratiadis A. 'Designer' tumors in mice. Oncogene. 2004;23(8):1558-1565.
3. Klinakis A, Szabolcs M, Chen G, Xuan S, Hibshoosh H, Efstratiadis A. Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci USA. 2009;106(7):2359-2364.
4. Ma J, Jemal A. The rise and fall of cancer mortality in the USA: why does pancreatic cancer not follow the trend? Future Oncol. 2013;9(7):917-919.
5. Perez-Mancera PA, Guerra C, Barbacid M, Tuveson DA. What we have learned about pancreatic cancer from mouse models. Gastroenterology. 2012;142(5):1079-1092.
6. Guerra C, Barbacid M. Genetically engineered mouse models of pancreatic adenocarcinoma. Mol Oncol. 2013;7(2):232-247.
7. Murtaugh LC. Pathogenesis of Pancreatic Cancer: Lessons from Animal Models. Toxicol Pathol. 2014;42(1):217-228
8. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4(6):437-450.
9. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7(5):469-483.
10. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15(24):3243-3248.
11. Ling J, Kang Y, Zhao R, et al. KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(1):105-120.
12. Tuveson DA, Shaw AT, Willis NA, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell. 2004;5(4):375-387.
13. Ludwig T, Fisher P, Murty V, Efstratiadis A. Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice. Oncogene. 2001;20(30):3937-3948.
14. de Alboran IM, O'Hagan RC, Gartner F, et al. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity. 2001;14(1):45-55.
15. Wu X, Wu J, Huang J, et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev. 2001;101(1-2):61-69.
16. Kiessling A, Wiesinger R, Sperl B, Berg T. Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]pyrimidine. Chem Med Chem 2007;2(5):627-630.
17. Berg T. Small-molecule modulators of c-Myc/Max and Max/Max interactions. Curr Top Microbiol Immunol. 2011;348:139-149.
18. Sofianos ZD, Katsila T, Kostomitsopoulos N, et al. In vivo evaluation and in vitro metabolism of leuprolide in mice-mass spectrometrybased biomarker measurement for efficacy and toxicity. J Mass Spectrom. 2008;43(10):1381-1392.
19. Ji B, Tsou L, Wang H, et al. Ras activity levels control the development of pancreatic diseases. Gastroenterology. 2009;137(3):1072-1082.
20. Konishi H, Karakas B, Abukhdeir AM, et al. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Res. 2007;67(18):8460-8467.
21. Grützmann R, Pilarsky C, Ammerpohl O, et al. Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia. 2004;6(5):611-622.
22. Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology. 2008;55(88):2016-2027.
23. Donahue TR, Tran LM, Hill R, et al. Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res. 2012;18(5):1352-1363.
24. Yeh E, Cunningham M, Arnold H, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004;6(4):308-318.
25. Soucek L, Whitfield J, Martins CP, et al. Modelling Myc inhibition as a cancer therapy. Nature. 2008;455(7213):679-683.
26. Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Mod Pathol. 2002;15(4):462-469.
27. Li YJ, Wei ZM, Meng YX, Ji XR. Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. World J Gastroenterol. 2005;11(14):2117-2123.
28. Lin WC, Rajbhandari N, Liu C, et al. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Res. 2013;73(6):1821-1830.
29. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Rasdependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14(19):2501-2514.
30. Bonal C, Thorel F, Ait-Lounis A, Reith W, Trumpp A, Herrera PL. Pancreatic inactivation of c-Myc decreases acinar mass and transdifferentiates acinar cells into adipocytes in mice. Gastroenterology. 2009;136(1):309-319.
31. Mazur PK, Einwachter H, Lee M, et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA. 2010;107(30):13438-13443.
32. Watson J. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol. 2013;3(1):120144.
33. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ. 1997;8(10):1039-1048.
34. Castelletti D, Fiaschetti G, Di Dato V, et al. The quassinoid derivative NBT-272 targets both the AKT and ERK signaling pathways in embryonal tumors. Mol Cancer Ther. 2010;9(12):3145-3157.
35. Guo J, Parise RA, Joseph E, et al. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5- [4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol. 2009;63(4):615-625.
36. Savino M, Annibali D, Carucci N, et al. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS One. 2011;6(7):e22284.
37. Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Buchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013;10(6):323-333.
38. Westphalen CB, Olive KP. Genetically engineered mouse models of pancreatic cancer. Cancer J. 2012;18(6):502-510.
39. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol. 2006;16(4):318-330.